Does Emtricitabine Rilpivirine Tenofovir Disoproxil Fumarate Interact with Mao Inhibitors?
CDI records a contraindicated classification for Emtricitabine Rilpivirine Tenofovir Disoproxil Fumarate and Mao Inhibitors. The stored summary is: Use of RPV with proton pump inhibitors is contraindicated due to decreased plasma concentrations of RPV and loss of virologic response. The mechanism involves drugs that increase gastric ph decrease rpv absorption. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Emtricitabine Rilpivirine Tenofovir Disoproxil Fumarate Class
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Drugs that increase gastric pH decrease RPV absorption
What To Tell Your Doctor or Pharmacist
If you are taking Emtricitabine Rilpivirine Tenofovir Disoproxil Fumarate and your doctor is considering prescribing Mao Inhibitors (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider